Sugi Predict

Sugi Predict / Compounds / SCHEMBL2479797

SCHEMBL2479797

SCHEMBL2479797

O=[N+]([O-])c1cc(Cl)c(Br)cc1F

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 3/20 0.46
▸ ATM Q13315 1/20 0.46
▸ ALDH1A1 P00352 4/20 0.44
▸ HIF1A Q16665 2/20 0.44
▸ PDE7A Q13946 1/20 0.44
▸ VCAM1 P19320 4/20 0.42
▸ MAPT P10636 2/20 0.41
▸ PKM P14618 1/20 0.41
▸ MAPK1 P28482 3/20 0.41
▸ TSHR P16473 2/20 0.41
▸ ESPL1 Q14674 1/20 0.41
▸ CYP3A4 P08684 3/20 0.39
▸ HPGD P15428 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ TXNRD1 Q16881 1/20 0.39
▸ TXNRD3 Q86VQ6 1/20 0.39
▸ TXNRD2 Q9NNW7 1/20 0.39
▸ GPR35 Q9HC97 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31702150 1.00 TDP1 (0.46) TDP1ATMALDH1A1HIF1APDE7A
SCHEMBL2596256 0.95 TDP1 (0.42) TDP1ATMALDH1A1HIF1APDE7A
SCHEMBL7872533 0.92 TDP1 (0.46) TDP1ATMALDH1A1HIF1APDE7A
SCHEMBL3252045 0.85 MAPT (0.49) TDP1ATMALDH1A1HIF1APDE7A
SCHEMBL29639886 0.85 MAPT (0.49) TDP1ATMALDH1A1HIF1APDE7A
SCHEMBL18905090 0.84 TDP1 (0.52) TDP1ATMALDH1A1HIF1AVCAM1
SCHEMBL123793 0.84 TDP1 (0.52) TDP1ATMALDH1A1HIF1APDE7A
SCHEMBL14578462 0.84 TDP1 (0.52) TDP1ATMALDH1A1HIF1APDE7A
SCHEMBL29580289 0.84 TDP1 (0.52) TDP1ATMALDH1A1HIF1APDE7A
SCHEMBL138641 0.82 TDP1 (0.50) TDP1ATMALDH1A1HIF1AVCAM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-12-25 — — US disclosed
US-20250376473-A1 PRMTS INHIBITOR AND USE THEREOF CYTOSINLAB THERAPEUTICS CO LTD (CN) 2025-12-11 — — US disclosed
US-12448388-B2 PRMT5 inhibitors and uses thereof GILEAD SCIENCES, INC. (US) 2025-10-21 — — US disclosed
US-12378232-B2 Cyclin dependent kinase inhibitors PFIZER INC. (US) 2025-08-05 — — US disclosed
US-12378250-B2 Tricyclic compound as IRAK4 inhibitor KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2025-08-05 — — US disclosed
CN-119998278-A Compounds and uses thereof 福宏治疗公司 2025-05-13 — — CN disclosed
EP-4549442-A1 PRMT5 INHIBITORS AND USE THEREOF Cytosinlab Therapeutics Co., Ltd. (CN) 2025-05-07 — — EP disclosed
EP-4549440-A1 CLASS OF PRMT5 INHIBITORS AND USE THEREOF Cytosinlab Therapeutics Co., Ltd. (CN) 2025-05-07 — — EP disclosed
WO-2025056065-A1 CHEMOKINE RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION, AND USE 上海医药集团股份有限公司 2025-03-20 — — WO disclosed
EP-4522278-A1 BENZOYPARAZINE PYRAZINES ANE THEIR USES Foghorn Therapeutics Inc. (US) 2025-03-19 — — EP disclosed
US-20130065900-A1 PHARMACEUTICAL COMPOUNDS SENTINEL ONCOLOGY LIMITED (GB) 2013-03-14 — — US disclosed
US-20130065900-A1 PHARMACEUTICAL COMPOUNDS SENTINEL ONCOLOGY LIMITED (GB) 2013-03-14 — — US disclosed
WO-2012174340-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE LLC (US) 2012-12-20 — — WO disclosed
WO-2011141716-A2 PHARMACEUTICAL COMPOUNDS SENTINEL ONCOLOGY LIMITED (GB) 2011-11-17 — — WO disclosed
WO-2011141716-A2 PHARMACEUTICAL COMPOUNDS SENTINEL ONCOLOGY LIMITED (GB) 2011-11-17 — — WO disclosed
EP-2370438-A1 IMIDAZO [1,2A]PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION Exelixis, Inc. (US) 2011-10-05 — — EP disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 — — US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 — — US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 — — US disclosed
WO-2010065760-A1 IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION EXELIXIS, INC. (US) 2010-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT1, PRMT5, PRMT6 TDP1 161/4885ATM 461/4885ALDH1A1 3522/4885
US-12378250-B2 Tricyclic compound as IRAK4 inhibitor IRAK4, IRAK1, IRAK2 TDP1 568/4885ATM 1094/4885ALDH1A1 2912/4885
US-12448388-B2 PRMT5 inhibitors and uses thereof PRMT5, PRMT1, PRMT9 TDP1 84/4885ATM 266/4885ALDH1A1 3212/4885
US-20130065900-A1 PHARMACEUTICAL COMPOUNDS CSNK1A1, FRK, CSNK1E TDP1 2393/4885ATM 883/4885ALDH1A1 3289/4885
US-12378232-B2 Cyclin dependent kinase inhibitors CCNY, CCNI, CCNK TDP1 3146/4885ATM 696/4885ALDH1A1 4211/4885
US-20250376473-A1 PRMTS INHIBITOR AND USE THEREOF PRMT5, PRMT1, PRMT6 TDP1 666/4885ATM 535/4885ALDH1A1 3032/4885
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using S1PR1, S1PR5, S1PR3 TDP1 1560/4885ATM 4299/4885ALDH1A1 1246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.